NCT05710666View on ClinicalTrials.gov

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

March 30, 2028

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

trastuzumab deruxtecan (T-DXd) (IV)

Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.

Trial Locations (5)

Unknown

University Hospital Galway, Galway

Cork University Hospital, Cork

University Hospital Limerick, Limerick

D4

Saint Vincent's University Hospital, Dublin

D9

Beaumont Hospital, Dublin

All Listed Sponsors

lead

Cancer Trials Ireland

NETWORK

NCT05710666 - Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | Biotech Hunter | Biotech Hunter